Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 2:17:627-37.

Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation

Affiliations

Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation

Jiangping Hou et al. Mol Vis. .

Abstract

Purpose: To investigate the safety and inhibitory effects of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) on ocular cell proliferation and collagen matrix contraction.

Methods: For the antiproliferation studies, various ocular cell monolayers were exposed to HDP-PMEG, PMEG, 5-fluorouracil (5-FU), and daunorubicin (DNB). For the collagen contraction studies, retinal pigment epithelium (RPE) cells seeded onto type I collagen lattices were exposed for a single 5- or 50-min period to various concentrations of HDP-PMEG or 5-FU. For the cytotoxicity study, trypan blue exclusion tests were performed using a human Müller cell line. Cytotoxicity was determined up to 4 days after treatment.

Results: The proliferation of RPE cells, scleral fibroblasts, vessel endothelial cells, and ocular melanoma cells can all be significantly inhibited by HDP-PMEG. Its inhibitory effects on those cells were uniformly stronger than that of 5-FU. Contraction of the collagen matrix containing RPE cells was significantly inhibited by HDP-PMEG and by 5-FU at concentrations of 20 µM and 2,000 µM, respectively, as compared with controls (p<0.05). The safety profile of HDP-PMEG was significantly better than 5-FU and daunorubicin. The ocular therapeutic index is 1,100 for HDP-PMEG, 17.2 for 5-FU, and 1.25 for daunorubicin.

Conclusions: HDP-PMEG possesses a significant inhibitory effect on the proliferation of RPE, retinal glial cells, scleral fibroblasts, and ocular melanoma cells. HDP-PMEG is also genotoxic and may be used as a single short application for the modulation of unwanted ocular proliferation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structure of PMEG and HDP-PMEG.
Figure 2
Figure 2
MTS cell proliferation assay. Upper panel: proliferation assay on ARPE19 cell. Center panel: proliferation assay on Muller cell. Bottom panel: proliferation on EA-HY926 endothelium cell.
Figure 3
Figure 3
MTS cell proliferation assay to demonstrate the inhibitory effect on proliferation of the three melanoma cell lines: M23 cell (Upper panel), OCM1 cell (Center panel), and SP6.5 cell (Bottom panel). For M23 and SP6.5 cells, HDP-PMEG demonstrated a similar inhibitory effect to 5-FU while HDP-PMEG had a consistent stronger inhibitory effect than 5-FU on the OCM1 cell. Daunorubicin had the strongest inhibitory effect on all the three cell lines.
Figure 4
Figure 4
Cytotoxicity assay on Müller cell. A: The percentage of trypan blue positive cells (y-axis) was plotted against the concentration of the test compounds used (x-axis). The concentration unit was micro molar and the open box represented a 95% confidence limit. 5-FU at 100 µM that was the highest concentration tested, caused 20% death of the cell culture, which was equivalent to HDP-PMEG at 11 µM or DNR at 0.1 µM. B: Exemplary images from the Müller cell cytotoxicity study: the upper left panel showing a counting field from the control in which 31 cells were stained by trypan blue out of a total of 435 cells, yielding a 7% trypan blue positive rate. The rest of the three fields had a trypan blue positive rate of 19% (38/198) for 10 µM HDP-PMEG, 18% (46/251) for 100 µM 5-FU, and 18% (49/274) for 0.1 µM daunorubicin (DNR).
Figure 5
Figure 5
The ARPE19 cell proliferation inhibitory effect from single short-term exposure of HDP-PMEG and 5-FU. A: Following a 50-min contact, 2 µM and 6.32 µM HDP-PMEG inhibited cell proliferation by 50% and 75%, respectively, which were equivalent to 200 µM and 2,000 µM of 5-FU. The 5-min exposure also induced significant proliferation inhibition. However, the inhibition was consistently less than that from 50-min exposure cross all concentrations. The mark on the top of each bar represents the standard deviation. B: The Müller cell proliferation inhibitory effect from a single short-term exposure of HDP-PMEG and 5-FU. Both 5- and 50-min exposure induced dose dependent inhibition by 5-FU and HDP-PMEG. In a 50-min exposure, 2 µM HDP-PMEG induced a similar growth inhibition as that observed by 200 µM 5-FU. C: The anterior scleral fibroblast proliferation inhibitory effect from a single short-term exposure of HDP-PMEG and 5-FU. For the anterior scleral fibroblasts, a 20 µM HDP-PMEG 5-min exposure induced a 65% inhibition while even 20 mM 5-FU did not achieve the similar magnitude growth inhibition.

References

    1. Eibl KH, Fisher SK, Lewis GP. Alkylphosphocholines: a new approach to inhibit cell proliferation in proliferative vitreoretinopathy. Dev Ophthalmol. 2009;44:46–55. - PubMed
    1. Campochiaro PA. Pathogenic Mechanisms in Proliferative Vitreoretinopathy. Arch Ophthalmol. 1997;115:237–41. - PubMed
    1. Sydorova M, Lee MS. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res. 2005;37:188–90. - PubMed
    1. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126:550–9. - PubMed
    1. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114:698–704. - PubMed

Publication types

LinkOut - more resources